the excellent in-vitro activities of the newer beta-lactam agents ( ceftriaxone , cefotaxime and , particularly , imipenem ) and vancomycin against penicillin-resistant pneumococci offer a considerable promise for their use in the treatment of pneumococcal meningitis caused by these strains .
C0042313
vancomycin
C0025295
pneumococcal meningitis